Literature DB >> 31119434

Treatment trends in head and neck cancer: Surveillance, Epidemiology, and End Results (SEER) Patterns of Care analysis.

Jennifer A Schlichting1, Nitin A Pagedar2, Catherine Chioreso1, Charles F Lynch1,3, Mary E Charlton4,5.   

Abstract

PURPOSE: Recent advances in head and neck cancer (HNC) treatment, such as increased use of organ-preserving advanced radiation treatments, the approval of cetuximab for HNC treatment, and the increase in human papillomavirus (HPV)-related HNC, have changed clinical approaches to HNC management. We sought to identify treatment trends in a population-based cohort of HNC patients.
METHODS: The Surveillance, Epidemiology, and End Results Patterns of Care program collected additional treatment and HPV testing information on stratified random samples of HNC patients diagnosed in 1997 (n = 473), 2004 (n = 1,317), and 2009 (n = 1,128). Rao-Scott Chi-square tests were used to examine unadjusted associations between year of diagnosis and patient sociodemographic, tumor, and treatment characteristics. Cochran-Armitage tests for trend were used to examine the hypothesis that certain treatments were used increasingly (or decreasingly) over the time period, while logistic regression was used to examine factors associated with particular treatments.
RESULTS: Use of radiation and chemotherapy without surgery significantly increased for all HNC sites between 1997 and 2009. Cetuximab and taxane use also showed a significantly increasing trend. Lack of insurance was associated with not receiving treatment in multivariate models. The majority (64%) of cases undergoing radiation in 2009 received an advanced treatment, with 55% receiving intensity modulated. The majority of oropharyngeal cases with known HPV status received chemotherapy and radiation only (62%) and nearly all were insured and had one or fewer comorbidities.
CONCLUSIONS: Treatment patterns have changed for HNC, leading to increased incorporation of systemic therapy and newer radiation techniques. HPV testing should be targeted for more widespread use, especially in traditionally underserved groups.

Entities:  

Keywords:  Cetuximab; Chemotherapy; Head and neck cancer; Human papillomavirus; Radiation

Mesh:

Year:  2019        PMID: 31119434      PMCID: PMC6668728          DOI: 10.1007/s10552-019-01185-z

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  45 in total

Review 1.  Intensity-modulated radiotherapy: current status and issues of interest.

Authors: 
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-11-15       Impact factor: 7.038

Review 2.  The expanding role of systemic therapy in head and neck cancer.

Authors:  Ezra E W Cohen; Mark W Lingen; Everett E Vokes
Journal:  J Clin Oncol       Date:  2004-05-01       Impact factor: 44.544

3.  Carcinogenicity of human papillomaviruses.

Authors:  Vincent Cogliano; Robert Baan; Kurt Straif; Yann Grosse; Béatrice Secretan; Fatiha El Ghissassi
Journal:  Lancet Oncol       Date:  2005-04       Impact factor: 41.316

4.  Cetuximab approved by FDA for treatment of head and neck squamous cell cancer.

Authors: 
Journal:  Cancer Biol Ther       Date:  2006-04       Impact factor: 4.742

Review 5.  Radiation-induced xerostomia.

Authors:  Mark S Chambers; David I Rosenthal; Randal S Weber
Journal:  Head Neck       Date:  2007-01       Impact factor: 3.147

6.  Quality of life and oral function in patients treated with radiation therapy for head and neck cancer.

Authors:  J B Epstein; M Robertson; S Emerton; N Phillips; P Stevenson-Moore
Journal:  Head Neck       Date:  2001-05       Impact factor: 3.147

Review 7.  Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis.

Authors:  Jean Bourhis; Jens Overgaard; Hélène Audry; Kian K Ang; Michele Saunders; Jacques Bernier; Jean-Claude Horiot; Aurélie Le Maître; Thomas F Pajak; Michael G Poulsen; Brian O'Sullivan; Werner Dobrowsky; Andrzej Hliniak; Krzysztof Skladowski; John H Hay; Luiz H J Pinto; Carlo Fallai; Karen K Fu; Richard Sylvester; Jean-Pierre Pignon
Journal:  Lancet       Date:  2006-09-02       Impact factor: 79.321

Review 8.  Radiation-induced xerostomia in patients with head and neck cancer: pathogenesis, impact on quality of life, and management.

Authors:  Mark S Chambers; Adam S Garden; Merrill S Kies; Jack W Martin
Journal:  Head Neck       Date:  2004-09       Impact factor: 3.147

9.  Quality of life in patients with oropharynx carcinomas: assessment after accelerated radiotherapy with or without chemotherapy versus radical surgery and postoperative radiotherapy.

Authors:  Abdelkarim S Allal; Kevin Nicoucar; Nicolas Mach; Pavel Dulguerov
Journal:  Head Neck       Date:  2003-10       Impact factor: 3.147

10.  Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.

Authors:  James A Bonner; Paul M Harari; Jordi Giralt; Nozar Azarnia; Dong M Shin; Roger B Cohen; Christopher U Jones; Ranjan Sur; David Raben; Jacek Jassem; Roger Ove; Merrill S Kies; Jose Baselga; Hagop Youssoufian; Nadia Amellal; Eric K Rowinsky; K Kian Ang
Journal:  N Engl J Med       Date:  2006-02-09       Impact factor: 91.245

View more
  9 in total

1.  Does low-level laser therapy affect the survival of patients with head and neck cancer?

Authors:  Rene Fischlechner; Barbara Kofler; Volker Hans Schartinger; Jozsef Dudas; Herbert Riechelmann
Journal:  Lasers Med Sci       Date:  2020-06-25       Impact factor: 3.161

2.  Head and neck cancer in Cali, Colombia: Population-based study.

Authors:  Natalia Aragón; Dora Ordoñez; María Fernanda Urrea; Jorge Holguín; Paola Collazos; Luz Stella García; María C Osorio; José M Barreto; Luis Eduardo Bravo
Journal:  Community Dent Oral Epidemiol       Date:  2021-06-08       Impact factor: 2.489

Review 3.  Biological roles and clinical significance of estrogen and androgen receptors in head and neck cancers.

Authors:  Chunhong Qin; Yan Lu; Huimin Zhang; Zhe Zhang; Wei Xu; Shuxin Wen; Wei Gao; Yongyan Wu
Journal:  J Cancer       Date:  2022-04-04       Impact factor: 4.478

4.  Epidemiological trends of head and neck Cancer survivors in Alberta: towards improved understanding of the burden of disease.

Authors:  Jin Soo Song; Patrick Vallance; Vincent Biron; Caroline C Jeffery
Journal:  J Otolaryngol Head Neck Surg       Date:  2020-07-06

5.  Trends in Treatment of Head and Neck Cancer in Germany: A Diagnosis-Related-Groups-Based Nationwide Analysis, 2005-2018.

Authors:  Isabel Hermanns; Rafat Ziadat; Peter Schlattmann; Orlando Guntinas-Lichius
Journal:  Cancers (Basel)       Date:  2021-12-01       Impact factor: 6.639

6.  Dysphagia, hypothyroidism, and osteoradionecrosis after radiation therapy for head and neck cancer.

Authors:  Pihla Ranta; Eero Kytö; Linda Nissi; Ilpo Kinnunen; Tero Vahlberg; Heikki Minn; Eeva Haapio; Lassi Nelimarkka; Heikki Irjala
Journal:  Laryngoscope Investig Otolaryngol       Date:  2021-12-10

7.  Effects of Immunonutrition in Head and Neck Cancer Patients Undergoing Cancer Treatment - A Systematic Review.

Authors:  Sing Ean Tan; Nur Fadhlina Abdul Satar; Hazreen Abdul Majid
Journal:  Front Nutr       Date:  2022-02-25

Review 8.  Global burden of ototoxic hearing loss associated with platinum-based cancer treatment: A systematic review and meta-analysis.

Authors:  Lauren K Dillard; Lucero Lopez-Perez; Ricardo X Martinez; Amanda M Fullerton; Shelly Chadha; Catherine M McMahon
Journal:  Cancer Epidemiol       Date:  2022-06-17       Impact factor: 2.890

Review 9.  The Research Progression and Clinical Significance of Circular RNAs in Head and Neck Cancers.

Authors:  Danhui Wang; Zhi Li; Yongjun Wu
Journal:  Biomed Res Int       Date:  2020-10-21       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.